drugset

drugset / Trial / NCT03925662

Mebendazole as Adjuvant Treatment for Colon Cancer

NCT03925662 ↗

Phase 3 Recruiting 40 enrolled Tanta University

RandomizedParallel-groupOpen-labelTreatment

Summary

mebendazole treating colon cancer

Timeline

Start: 2019-04-01
Primary completion: 2028-12
Completion: 2028-12

Publications

Hegazy SK, El-Azab GA, Zakaria F, Mostafa MF, El-Ghoneimy RA. Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer. Life Sci. 2022 Jun 15;299:120536. doi: 10.1016/j.lfs.2022.120536. Epub 2022 Apr 3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mebendazole	Small molecule	500 mg	Oral
Comparator	Bevacizumab	Monoclonal antibody	—	—

Indications